These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 22307838)

  • 1. The dark side of mast cell-targeted therapy in prostate cancer.
    Pittoni P; Colombo MP
    Cancer Res; 2012 Feb; 72(4):831-5. PubMed ID: 22307838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mast cell targeting hampers prostate adenocarcinoma development but promotes the occurrence of highly malignant neuroendocrine cancers.
    Pittoni P; Tripodo C; Piconese S; Mauri G; Parenza M; Rigoni A; Sangaletti S; Colombo MP
    Cancer Res; 2011 Sep; 71(18):5987-97. PubMed ID: 21896641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunological microenvironment in prostate cancer: high mast cell densities are associated with favorable tumor characteristics and good prognosis.
    Fleischmann A; Schlomm T; Köllermann J; Sekulic N; Huland H; Mirlacher M; Sauter G; Simon R; Erbersdobler A
    Prostate; 2009 Jun; 69(9):976-81. PubMed ID: 19274666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-intrinsic and -extrinsic roles of c-Kit: mast cells as the primary off-target of tyrosine kinase inhibitors.
    Pittoni P; Piconese S; Tripodo C; Colombo MP
    Oncogene; 2011 Feb; 30(7):757-69. PubMed ID: 21057534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Focal degeneration of basal cells and the resultant auto-immunoreactions: a novel mechanism for prostate tumor progression and invasion.
    Man YG; Gardner WA
    Med Hypotheses; 2008; 70(2):387-408. PubMed ID: 17658698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective expression of CD44, a putative prostate cancer stem cell marker, in neuroendocrine tumor cells of human prostate cancer.
    Palapattu GS; Wu C; Silvers CR; Martin HB; Williams K; Salamone L; Bushnell T; Huang LS; Yang Q; Huang J
    Prostate; 2009 May; 69(7):787-98. PubMed ID: 19189306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mast cells and cancer--no longer just basic science.
    Galinsky DS; Nechushtan H
    Crit Rev Oncol Hematol; 2008 Nov; 68(2):115-30. PubMed ID: 18632284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of a truncated form of the c-Kit tyrosine kinase receptor and activation of Src kinase in human prostatic cancer.
    Paronetto MP; Farini D; Sammarco I; Maturo G; Vespasiani G; Geremia R; Rossi P; Sette C
    Am J Pathol; 2004 Apr; 164(4):1243-51. PubMed ID: 15039213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors.
    Cussenot O; Villette JM; Cochand-Priollet B; Berthon P
    Prostate Suppl; 1998; 8():43-51. PubMed ID: 9690663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mast cell expression of gelatinases A and B is regulated by kit ligand and TGF-beta.
    Fang KC; Wolters PJ; Steinhoff M; Bidgol A; Blount JL; Caughey GH
    J Immunol; 1999 May; 162(9):5528-35. PubMed ID: 10228034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production.
    Sweeney P; Karashima T; Kim SJ; Kedar D; Mian B; Huang S; Baker C; Fan Z; Hicklin DJ; Pettaway CA; Dinney CP
    Clin Cancer Res; 2002 Aug; 8(8):2714-24. PubMed ID: 12171905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A critical role for mast cells and mast cell-derived IL-6 in TLR2-mediated inhibition of tumor growth.
    Oldford SA; Haidl ID; Howatt MA; Leiva CA; Johnston B; Marshall JS
    J Immunol; 2010 Dec; 185(11):7067-76. PubMed ID: 21041732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment.
    Chung LW; Baseman A; Assikis V; Zhau HE
    J Urol; 2005 Jan; 173(1):10-20. PubMed ID: 15592017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphatidylinositol 3'-kinase is required for growth of mast cells expressing the kit catalytic domain mutant.
    Shivakrupa R; Bernstein A; Watring N; Linnekin D
    Cancer Res; 2003 Aug; 63(15):4412-9. PubMed ID: 12907613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo.
    Raffo AJ; Perlman H; Chen MW; Day ML; Streitman JS; Buttyan R
    Cancer Res; 1995 Oct; 55(19):4438-45. PubMed ID: 7671257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent C-kit mutation.
    Beghini A; Cairoli R; Morra E; Larizza L
    Blood Cells Mol Dis; 1998 Jun; 24(2):262-70. PubMed ID: 9714703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of Kit expression by IL-4 and IL-10 in murine mast cells: role of STAT6 and phosphatidylinositol 3'-kinase.
    Mirmonsef P; Shelburne CP; Fitzhugh Yeatman C; Chong HJ; Ryan JJ
    J Immunol; 1999 Sep; 163(5):2530-9. PubMed ID: 10452990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells.
    Yuan TC; Veeramani S; Lin MF
    Endocr Relat Cancer; 2007 Sep; 14(3):531-47. PubMed ID: 17914087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mast cell: insight into remodeling a tumor microenvironment.
    Liu J; Zhang Y; Zhao J; Yang Z; Li D; Katirai F; Huang B
    Cancer Metastasis Rev; 2011 Jun; 30(2):177-84. PubMed ID: 21267769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant expression of stem cell factor on biliary epithelial cells and peribiliary infiltration of c-kit-expressing mast cells in hepatolithiasis and primary sclerosing cholangitis: a possible contribution to bile duct fibrosis.
    Tsuneyama K; Kono N; Yamashiro M; Kouda W; Sabit A; Sasaki M; Nakanuma Y
    J Pathol; 1999 Dec; 189(4):609-14. PubMed ID: 10629565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.